CERS · Cerus Corp
$3.15
+0.02 (+0.64%)
At close · Jul 20
Market Cap
$631.16M
Shares
200.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.15
Open$3.13
Day$3.11–3.23
52W$1.15–3.47
Avg vol 30d2.5M
Short int12.7M · 6.4% float · 4.1d
Short vol47%
Last earningsJul 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Up next
Next earnings call
Jul 30, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
+13%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
+28%
trailing
YTD return
+53%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
20 of 168 funds reported for Jun 30 · net -2.8M sh shares · +5 new
Insider flow
Distributing
Net -$153.2K over 90 days · 100% sells
Short interest
Falling
6.36% of float · ▼ -35.3% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
168 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
33%
expanding
EPS growth
+27%
Y/Y
Free cash flow
$1.1M
Balance sheet
$15.1M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 30, 2026
Full-year 2026 product revenue
· full-year 2026
Initiated
$227M – $231M
prior FY $233.8M
midpoint −2.1% Y/Y
Full-year 2026 IFC revenue
· full-year 2026
Initiated
$22M – $24M
Guided vs delivered
· last 1 settled
Full year 2025 product revenue
full year 2025
guided $200M – $203M
$233.8M
Beat +16.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
20 of 168 funds reported for Jun 30 · net -2.8M sh shares · +5 new
Insider flow
Distributing
Net -$153.2K over 90 days · 100% sells
Short interest
Falling
6.36% of float · ▼ -35.3% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
168 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $3 · 86%
52-wk high $3
vs 200-day avg +45%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| U.S. IFC sales | $5.7M | Q1 2026 | — |
| adjusted EBITDA non-GAAP | $4M | Q1 FY2026 call | — |
| IFC demand (therapeutic dose equivalents) | 120% | Q1 2026 call | — |
| IFC demand growth (therapeutic dose equivalent) | 120% | Q1 FY2026 call | — |
| IFC revenue growth | 90% | Q1 FY2026 call | — |
| ISC demand | 120% | first quarter call | — |
| non-GAAP adjusted EBITDA non-GAAP | $4M | first quarter call | — |
|
|
|||
| North America share of product revenue | 70% | Q1 FY2026 call | — |
| North American platelet kit volumes (treatable doses) | 69% | Q1 2026 call | — |
| U.S. IFC revenue | $5.7M | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CERS
this stock
Cerus Corp
|
$631.16M | +52.9% | +30.7% | — | 6.4% |
|
ABT
Abbott Laboratories
|
$177.07B | -18.4% | +5.7% | 28.5 | 1.3% |
|
SYK
Stryker Corp
|
$122.35B | -9.0% | +11.2% | 36.9 | 1.8% |
|
MDT
Medtronic plc
|
$106.61B | -12.6% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.06B | -54.1% | +5.5% | 18.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CERS | +1.9% | +16.7% | +28.1% | +7.9% | +52.9% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | +2.9% | +17.3% | +20.9% | +8.5% | +44.1% |
Key facts
CIK
1020214
CUSIP
157085101
13F (30d)
21 filings
19 filers
Visit website
Investor relations